KYUNG DONG PHARMACEUTICAL Co., Ltd

As of March 31, 2026, KYUNG DONG PHARMACEUTICAL Co., Ltd carries a market capitalization of 159.98B, placing it among publicly traded companies globally. Its enterprise value stands at 156.64B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, KYUNG DONG PHARMACEUTICAL Co., Ltd has 29.30M shares outstanding.

As of March 31, 2026, KYUNG DONG PHARMACEUTICAL Co., Ltd trades at a trailing price-to-earnings ratio of 12.76. The price-to-sales ratio is 0.75, and the price-to-book ratio stands at 0.70.

As of March 31, 2026, KYUNG DONG PHARMACEUTICAL Co., Ltd trades at an EV/EBITDA multiple of 12.65 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.33 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 156.64B versus a market cap of 159.98B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, KYUNG DONG PHARMACEUTICAL Co., Ltd maintains a current ratio of 1.63, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.12, indicating elevated leverage, while an interest coverage ratio of 6.91 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, KYUNG DONG PHARMACEUTICAL Co., Ltd posted a return on equity (ROE) of 5.25, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.93 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.82, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.26, useful for judging operating efficiency across full business cycles. The company generates approximately 531.57M in revenue per employee across its workforce of 373.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.73 indicates how many times KYUNG DONG PHARMACEUTICAL Co., Ltd sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, KYUNG DONG PHARMACEUTICAL Co., Ltd recorded 1.69B in income tax expense. That works out to an effective tax rate of 12.78, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 13.24B, leaving 11.63B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, KYUNG DONG PHARMACEUTICAL Co., Ltd's stock has declined approximately 15.95% over the past 52 weeks. The 50-day moving average sits at 5,061.00, while the 200-day moving average is 5,305.80.

Over the twelve months ended March 31, 2026, KYUNG DONG PHARMACEUTICAL Co., Ltd generated 198.27B in revenue and converted that into 11.63B in net income, yielding earnings per share of 423.21. EBITDA reached 12.38B, while operating income came in at 8.55B.

As of March 31, 2026, KYUNG DONG PHARMACEUTICAL Co., Ltd holds 29.37B in cash and equivalents against 25.54B in total debt, resulting in a net debt position of 9.65B. Total book value stands at 229.10B, with working capital of 35.04B providing operational flexibility.

KYUNG DONG PHARMACEUTICAL Co., Ltd produced 17.09B in operating cash flow over the twelve months ended March 31, 2026. After subtracting -18.91B in capital expenditures, free cash flow totaled -1.82B - equivalent to -67.13 per share.

Over the twelve months ended March 31, 2026, KYUNG DONG PHARMACEUTICAL Co., Ltd posted a gross margin of 59.77, reflecting its pricing power and cost economics. The operating margin of 4.31 and net profit margin of 5.87 provide insight into operational efficiency.

Over the twelve months ended March 31, 2026, KYUNG DONG PHARMACEUTICAL Co., Ltd paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -1.22: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 10.77, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to KYUNG DONG PHARMACEUTICAL Co., Ltd shareholders.

KYUNG DONG PHARMACEUTICAL Co., Ltd's most recent stock split took place on May 15, 2018 with a 1:2 split ratio.

As of March 31, 2026, KYUNG DONG PHARMACEUTICAL Co., Ltd has an Altman Z-Score of 3.02, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.